Drug intelligence / Profile preview

LV201R

Development stage: Preclinical
Lead developer: LivFul
Modality: Small Molecules
Administration: Oral

Overview

LV201R is a preclinical-stage small molecule therapeutic being developed by LivFul, primarily for the treatment of glioblastoma. It is characterized by a preclinical profile similar to LV101R, demonstrating both anti-tumor and anti-angiogenic activities. Positioned as a potential broad-spectrum cancer therapy and a replacement for conventional chemotherapy, LV201R is formulated for oral administration as a tablet.

Other names: LV201RLV-201RLV 201R

Beyond the preview

Go deeper on LV201R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LV201R.

Explore the full profile